Nakagawa et al. reported that the clinical performance of the OSNA assay for rare cancer types other than adenocarcinoma and squamous cell carcinoma requires additional evaluation owing to the limited number of low-incidence histological types because there were some cases with low CK19 expression in pleomorphic carcinoma and large cell carcinoma [7]. This evidence concerns the gene KRT19 and large cell carcinoma.